.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has actually filed to debut on everyone market.The Eli Lilly-partnered biotech wish to list on the Nasdaq under the sign "BIOA," according to papers filed with the Stocks and also Exchange Commission. The provider has actually not publicly discussed an expected financial amount for the offering.The clinical-stage business touts lead prospect azelaprag, a by mouth delivered little particle slated to enter into stage 2 screening in combination with semaglutide-- offered through Novo Nordisk under brand Wegovy for weight management-- in the very first half of upcoming year. Semaglutide is actually likewise sold as Ozempic and also Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually made to blend well with GLP-1 medicines, increasing fat loss while maintaining muscle mass. The investigational medication was actually found to be well-tolerated amongst 265 individuals throughout 8 phase 1 tests, according to BioAge.Previously, BioAge achieved the support of Lilly to operate a test integrating azelaprag with the Significant Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes as Mounjaro as well as Zepbound for fat loss. The partners are presently conducting a phase 2 test of azelaprag and tirzepatide, with topline end results expected in the 3rd fourth of 2025.The biotech is actually additionally planning an insulin sensitivity proof-of-concept trial examining azelaprag as a monotherapy in the initial one-half of next year to assist potential sign expansion. Additionally, the provider plans to ask the FDA for permission in the second one-half of 2025 to release individual screening for an NLRP3 inhibitor targeting metabolic health conditions and neuroinflammation.BioAge's anticipated transfer to everyone market follows a minor uptick in planned biotech IPOs coming from Bicara Rehabs and Zenas Biopharma. Zooming out, the latest IPO landscape is actually a "blended picture," along with high-grade providers still debuting on the general public markets, just in lowered amounts, depending on to PitchBook.